Editorial commentary: Escherichia coli O104:H4 and hemolytic uremic syndrome: The analysis begins

Clinical Infectious Diseases

Volumn 55, Issue 6, 2012, Pages 760-763

  Tarr, Phillip I ^a   Karpman, Diana ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; ECULIZUMAB;

BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPLEMENT ALTERNATIVE PATHWAY; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; EVIDENCE BASED MEDICINE; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOADSORPTION; MICROBIOLOGICAL EXAMINATION; NOTE; OUTCOME ASSESSMENT; PATHOGENESIS; PEER REVIEW; PHYSICIAN; PLASMAPHERESIS; PRIORITY JOURNAL; RISK FACTOR; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGA TOXIN PRODUCING ESCHERICHIA COLI INFECTION; SURVIVAL RATE; THERAPEUTIC PLASMA EXCHANGE; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; URINALYSIS;

DISEASE OUTBREAKS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MALE; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84865455610     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis533     Document Type: Note

References (44)

1. Loos S, et al. An outbreak of Shiga-toxin producing E. coli O104:H4 hemolytic uremic syndrome (STEC-HUS) in Germany: presentation and short-term outcome in children. 2012:CID will supply pagination.
2. Banatvala N, Griffin PM, Greene KD, et al. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis 2001; 183:1063-70. (Pubitemid 32230954)
3. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930-6. (Pubitemid 30419087)
4. Tsai H-M, Chandler WL, Sarode R, et al. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res 2001; 49:653-9. (Pubitemid 32390854)
5. Jelacic S, Wobbe CL, Boster DR, et al. ABO and P1 blood group antigen expression and stx genotype and outcome of childhood Escherichia coli O157:H7 infections. J Infect Dis 2002; 185:214-9. (Pubitemid 34056445)
6. Cornick NA, Jelacic S, Ciol MA, Tarr PI. Escherichia coli O157:H7 infections: discordance between filterable fecal Shiga toxin and disease outcome. J Infect Dis 2002; 186:57-63. (Pubitemid 34666914)
7. Klein EJ, Stapp JR, Clausen CR, et al. Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. J Pediatr 2002; 141:172-7.
8. Jelacic JK, Damrow T, Chen GS, et al. Shiga toxin-producing Escherichia coli in Montana: bacterial genotypes and clinical profiles. J Infect Dis 2003; 188:719-29. (Pubitemid 37115185)
9. Smith JM, Jones F, Ciol MA, et al. Plateletactivating factor and Escherichia coli O157:H7 infections. Pediatr Nephrol 2002; 17:1047-52. (Pubitemid 36097650)
10. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005; 115:e681-9. (Pubitemid 43843141)
11. Hickey CA, Beattie TJ, Cowieson J, et al. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011; 165:884-9.
12. Zimmerhackl L-B, Rosales A, Hofer J, et al. Enterohemorrhagic Escherichia coli O26: H11-associated hemolytic uremic syndrome: bacteriology and clinical presentation. Semin Thromb Hemost 2010; 36:586-93.
13. Gerber A, Karch H, Allerberger F, Verweyen HMZimmerhackl LB. Clinical course and the role of Shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis 2002; 186:493-500. (Pubitemid 34876258)
14. Bielaszewska M, Middendorf B, ck RK, et al. Shiga toxin-negative attaching and effacing Escherichia coli: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution. Clin Infect Dis 2008; 47:208-17. (Pubitemid 351920622)
15. Bielaszewska M, Köck R, Friedrich AW, et al. Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm? PLoS One 2007; 2:e1024.
16. Friedrich AW, Zhang W, Bielaszewska M, et al. Prevalence, virulence profiles, and clinical significance of Shiga toxin-negative variants of enterohemorrhagic Escherichia coli O157 infection in humans. Clin Infect Dis 2007; 45:39-45. (Pubitemid 46984613)
17. Bielaszewska M, Friedrich AW, Aldick T, Schürk-Bulgrin R, Karch H. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome. Clin Infect Dis 2006; 43:1160-7. (Pubitemid 44632799)
18. Sonntag A-K, Prager R, Bielaszewska M, et al. Phenotypic and genotypic analyses of enterohemorrhagic Escherichia coli O145 strains from patients in Germany. J Clin Microbiol 2004; 42:954-62. (Pubitemid 38332810)
19. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999; 52:357-62.
20. Tarr PI, Neill MA, Clausen CR, Watkins SL, Christie DL, Hickman RO. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 1990; 162:553-6. (Pubitemid 20239981)
21. Neill MA, Tarr PI, Clausen CR, Christie DL, Hickman RO. Escherichia coli O157:H7 as the predominant pathogen associated with the hemolytic uremic syndrome: a prospective study in the Pacific Northwest. Pediatrics 1987; 80:37-40. (Pubitemid 17091733)
22. Frank C, Werber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365:1771-80.
23. Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011; 11:671-6.
24. Galle J. Therapeutische Apheresebehandlung bei EHEC assoziiertem HUS. Available at: http ://www.dgfn.eu/aktuell/ehec-informationen/fuer-das- fachpublikum/therapeutischeapheresebehandlung-bei-ehec-assoziiertemhus/. Accessed 4 June 2012.
25. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shigatoxin-associated HUS. N Engl J Med 2011; 364:2561-3.
26. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V. Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011; 365:8-26.
27. Orth D, Khan AB, Naim A, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394-400.
28. Morigi M, Galbusera M, Gastoldi S, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187:172-80.
29. Stahl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117:5503-13.
30. Greinacher A, Friesecke S, Abel P, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104: H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011; 378:1166-73.
31. Hunt BJ, Lammle B, Nevard CH, Haycock GB, Furlan M. von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost 2001; 85:975-8. (Pubitemid 32573745)
32. Veyradier A, Obert B, Haddad E, et al. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 2003; 142:310-7. (Pubitemid 36338016)
33. Dundas S, Murphy J, Soutar RL, Jones GA, Hutchinson SJ, Todd WT. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999; 354:1327-30. (Pubitemid 29481627)
34. Szczepiorkowski ZM,Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the apheresis applications committee of the American Society for Apheresis. J Clin Apher 2010; 25:83-177.
35. Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378:1089-93.
36. Ruggenenti P, Remuzzi G. A German outbreak of haemolytic uraemic syndrome. Lancet 2011; 378:1057-8.
37. Lopez EL, Contrini MM, Glatstein E, et al. An epidemiologic surveillance of Shiga-like toxinproducing Escherichia coli infection in Argentinean children: risk factors and serum Shigalike toxin 2 values. Pediatr Infecti Dis J 2012; 31:20-4.
38. Siegler RL, Obrig TG, Pysher TJ, Tesh VL, Denkers ND, Taylor FB. Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome. Pediatr Nephrol 2003; 18:92-6. (Pubitemid 41490292)
39. Leung DY, Moake JL, Havens PL, Kim M, Pober JS. Lytic anti-endothelial cell antibodies in haemolytic-uraemic syndrome. Lancet 1988; 2:183-6.
40. Som S, Deford CC, Kaiser ML, et al. Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpurahemolytic uremic syndrome, 1996 to 2011 [published online ahead of print 15 April 2012]. Transfusion 2012: doi: 10.1111/j.1537-2995.2012.03646.x.
41. Rosales A, Hofer J, Zimmerhackl LB, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54: 1413-21.
42. Gould LH, Demma L, Jones TF, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, Foodborne Diseases Active Surveillance Network sites, 2000-2006. Clin Infect Dis 2009; 49:1480-5.
43. Pavia AT, Nichols CR, Green DP, et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990; 116:544-51. (Pubitemid 20124149)
44. Samuelsson O, Follin O, Rundgren M, Rylander C, Selga D, Ståhl A. HUS-epidemin sommaren 2011 var allvarlig. Lakartidningen, Volume 109, June 19, 2012.